US News recently released a table which cites Emerging Growth Biotech stocks that have seen returns in excess of 1,900% over the past 5 years.
They define “Biotechnology Stocks” as Companies who use genetic or protein engineering to create medicines to treat and prevent ailments, and could also make diagnostic products or equipment for service to these companies.
The top 5 are currently priced between $2 and $35 per share and include AADI Biosciences, Inc. (NASDAQ: AADI), Zivo Biosciences, Inc. (NASDAQ: ZIVO), Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), Chemomab Therapeutids, Inc. (NASDAQ: CMMB) and Prothena Corporation (NASDAQ: PRTA)
Here’s a company that could make their list in the short term:
Take a look at PetVivo Holdings, Inc. (NASDAQ: PETV), and ask yourself if you think it could make that list.
PetVivo (NASDAQ: PETV) is a veterinary biotech and biomedical device company primarily engaged in the business of translating or adapting human biotech and medical technology into products for commercial sale in the veterinary market to treat companion animals such as dogs and horses suffering from arthritis and other afflictions.
The Company just announced that VetCove, Inc. has agredd to distribute PetVivo’s theraprutic product, SPRYNG™ with OsteoCushion™ Technology.
VetCove owns and operates a licensed veterinarian ordering/purchasing platform used by over 13,000 veterinary hospitals to compare prices and purchase medications, food and veterinary supplies from multiple vendors at once.
PetVivo’s innovative therapeutic product, Spryng™ with OsteoCushion™ Technology, is a veterinary medical device comprised of millions of micronized hydrogel matrices, which are derived from natural components, collagen and elastin. OsteoCushion Technology provides both reinforcing natural joint support to replace and/or reinforce missing and damaged cartilage, as well as delivers natural scaffolding to help address tissue defects. These attributes offer a great solution to manage lameness and joint afflictions, such as osteoarthritis, for companion animals in a simple in-clinic treatment.
PetVivo (NASDAQ: PETV) stock has been beaten down from $11.00 per share in July, to a low of just over $2.00 or just under 80%. The stock put in a triple bottom at round the 2.50 mark and at the time of writing is putting in an uptick day at around $2.70 with its next resistance level of just over $5.00 per share.
Like the companies mentioned above, PetVivo Holdings, Inc. (NASDAQ: PETV) is engaged in biotech, and healthcare, but with the niche of being in the pet industry, a space that has been down over 82% in 2021 according to one of the most heavily traded biotech ETF’s (LABU).
As one of the very few pure-play biotech companies for the companion animal market, competition to invest in this company could become fierce.
The Company recently listed on the NASDAQ and raised approximately $11,254,000 from a registered public offering which closed August 13, 2021. Further, PetVivo Holdings, Inc. (NASDAQ: PETV) finished its last quarter with over $8.8 million.
They are currently using the proceeds from their offering to expand their sales and marketing efforts to gain veterinary acceptance and generate revenue from the sale of Spryng.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG™, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale in the fourth quarter of this year.
Just two months ago, Think Equity initated coverage on the stock with a $7.00 price target.
Think Equity in Summary stated the following:
“The company received net proceeds of $9.8 million from the capital raise in August. We expect the company to step up marketing to support the product rollout. At the forecast cash burn, the current cash position of $8.5 million should support operations through third calendar quarter of 2022.
We forecast revenues to grow from $0.3 million in FY 2022 to $12.0 million by FY 2024. We are modeling gross margins to expand from 11% to 65% over the same period. We expect EBITDA to improve from $(3.7) million in fiscal 2022 to $(2.4) million in 2024.”
The global veterinary surgical instruments market is estimated to reach USD 1,029.0 million by 2021 from USD 748.4 million in 2016, grow at a CAGR of 6.6% during the forecast period as reported by Research and Markets.
The companion animal osteoarthritis market in the United States is estimated at $4.4 billion, growing at about 7% annually. The market size only represents dogs and horses, as the company’s treatment currently is for dogs and horses. The company expects a feline product within six months that expands the available market.
PetVivo Holdings, Inc. (NASDAQ: PETV) is a company you need to look at if you want to capitalize on growth in the space.
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in an effective and time efficient manner.
The audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All Conferences are first announced on Twitter – Follow us on Twitter
All Conference replays emerge on our YouTube Channel – Subscribe to our YouTube Channel
If you believe your company, product or service is at the cusp of going mainstream, or you have an idea for an “Emerging Growth” company that might fit our model, contact us here.